Sign in

    Sarah Weber

    former Analyst at Piper Jaffray Companies

    Sarah Weber is a former Analyst at Piper Jaffray Companies, specializing in biotech and pharmaceutical equity research with notable coverage of firms including Ovid Therapeutics. She played a role in initiating coverage on Ovid and built financial models projecting key product revenues, demonstrating strong sector expertise and the application of thorough diligence in her reports. Her career includes analyst positions at Altium and Nantahala Capital Management before moving into senior leadership as Managing Director at StemPoint Capital. Throughout her trajectory, she has demonstrated robust analytical skills and holds a reputation for comprehensive industry coverage and thoughtful investment thesis development.

    Sarah Weber's questions to Ovid Therapeutics (OVID) leadership

    Sarah Weber's questions to Ovid Therapeutics (OVID) leadership • Q4 2017

    Question

    Sarah Weber of Piper Jaffray Companies asked about the blinded safety and tolerability data for OV935 in the dEE trial, the planned number and location of sites for the Fragile X Rocket study, and the company's strategy for its OV101 patent portfolio.

    Answer

    Executive Matthew During commented that in the dEE trial, the drug has been 'extremely well tolerated' so far, with patients titrating to the target dose. Executive Amit Rakhit added that the Rocket study will primarily use U.S. sites, with some international sites being explored. CEO Jeremy Levin stated that the company feels 'very good' about its patent strategy, which has secured protection for its compounds well into the 2030s.

    Ask Fintool Equity Research AI